[go: up one dir, main page]

UY30617A1 - Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones - Google Patents

Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones

Info

Publication number
UY30617A1
UY30617A1 UY30617A UY30617A UY30617A1 UY 30617 A1 UY30617 A1 UY 30617A1 UY 30617 A UY30617 A UY 30617A UY 30617 A UY30617 A UY 30617A UY 30617 A1 UY30617 A1 UY 30617A1
Authority
UY
Uruguay
Prior art keywords
amino
metilsulfonil
nonil
hidroxi
fenil
Prior art date
Application number
UY30617A
Other languages
English (en)
Inventor
Lyn Howard Jones
Graham Lunn
David Anthony Price
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of UY30617A1 publication Critical patent/UY30617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a compuestos de formula (1) y a procesos para la preparacion de, intermedios usados en la preparacion de, composiciones que contienen y usos de, tales derivados. Los compuestos de acuerdo con la presente invencion son utiles en diversas enfermedades, trastornos y cuadros, en particular, enfermedades, trastornos y cuadros inflamatorios, alérgicos y respiratorios.
UY30617A 2006-10-04 2007-10-02 Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones UY30617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82809906P 2006-10-04 2006-10-04

Publications (1)

Publication Number Publication Date
UY30617A1 true UY30617A1 (es) 2008-05-31

Family

ID=38947725

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30617A UY30617A1 (es) 2006-10-04 2007-10-02 Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones

Country Status (25)

Country Link
US (1) US20080090873A1 (es)
EP (1) EP2074094A1 (es)
JP (1) JP2010505810A (es)
KR (1) KR20090050104A (es)
CN (1) CN101522622A (es)
AP (1) AP2009004791A0 (es)
AR (1) AR063118A1 (es)
AU (1) AU2007303909A1 (es)
BR (1) BRPI0719270A2 (es)
CA (1) CA2665385A1 (es)
CL (1) CL2007002791A1 (es)
CO (1) CO6180437A2 (es)
CR (1) CR10700A (es)
EA (1) EA200900337A1 (es)
IL (1) IL197244A0 (es)
MA (1) MA30778B1 (es)
MX (1) MX2009002209A (es)
NO (1) NO20090910L (es)
PE (1) PE20080831A1 (es)
RS (1) RS20090137A (es)
TN (1) TN2009000112A1 (es)
TW (1) TW200823185A (es)
UY (1) UY30617A1 (es)
WO (1) WO2008041095A1 (es)
ZA (1) ZA200901320B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP6307091B2 (ja) 2012-12-18 2018-04-04 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
EP3556435B1 (en) 2016-12-14 2020-10-28 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
AU2018346709A1 (en) 2017-10-05 2020-04-16 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2021505569A (ja) * 2017-12-04 2021-02-18 フリードリヒ−アレクサンダー−ウニヴェルシテート エアランゲン−ニュルンベルク Ｍ２よりもｍ３に対して選択性を有するフルオロフェニル置換ムスカリン受容体リガンド
WO2021260441A1 (en) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) * 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
JP4616264B2 (ja) * 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
CN1910144B (zh) * 2004-01-22 2010-06-09 辉瑞大药厂 用于疾病治疗的磺胺衍生物
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
EP2074094A1 (en) 2009-07-01
BRPI0719270A2 (pt) 2014-03-11
EA200900337A1 (ru) 2009-10-30
AP2009004791A0 (en) 2009-04-30
MX2009002209A (es) 2009-03-16
CN101522622A (zh) 2009-09-02
KR20090050104A (ko) 2009-05-19
TW200823185A (en) 2008-06-01
AR063118A1 (es) 2008-12-30
IL197244A0 (en) 2009-12-24
CL2007002791A1 (es) 2008-04-11
AU2007303909A1 (en) 2008-04-10
PE20080831A1 (es) 2008-06-20
ZA200901320B (en) 2010-04-28
CR10700A (es) 2009-04-24
JP2010505810A (ja) 2010-02-25
TN2009000112A1 (fr) 2010-08-19
MA30778B1 (fr) 2009-10-01
NO20090910L (no) 2009-03-24
CA2665385A1 (en) 2008-04-10
RS20090137A (en) 2010-06-30
US20080090873A1 (en) 2008-04-17
CO6180437A2 (es) 2010-07-19
WO2008041095A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
UY30617A1 (es) Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones
ECSP066701A (es) Derivados de sulfonamida para el tratamiento de enfermedades
ECSP088717A (es) Derivados de amina
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CU23801B7 (es) Análogos de pirazol
ECSP066700A (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28819A1 (es) Derivados de formamida para el tratamiento de enfermedades
CU23537B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CU23532B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2007000054A (es) Derivados de amina
DOP2005000037A (es) Compuestos utiles para el tratamiento de enfermedades
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28810A1 (es) Compuestos utiles para el tratamiento de enfermedades
DOP2005000043A (es) Compuestos para el tratamiento de enfermedades
UY28816A1 (es) Compuestos para el tratamiento de enfermedades
DOP2004000902A (es) Compuestos utiles para el tratamiento de enfermedades
DOP2007000062A (es) Agentes antifúngicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170725